


Viral dynamics


- Viral dynamics is the mathematical study of virus infection and dynamics within individuals
- Viral dynamic models aim to explain pathogenesis and biological processes in a viral infection

Viral dynamics

- Viral dynamics is the mathematical study of virus infection and dynamics within individuals
- Viral dynamic models aim to explain pathogenesis and biological processes in a viral infection
- Target cell model^[1,2,3]:



$$\begin{aligned} \frac{dT}{dt} &= -\beta TV \\ \frac{dI_1}{dt} &= \beta TV - kI_1 \\ \frac{dI_2}{dt} &= kI_1 - \delta I_2 \\ \frac{dV}{dt} &= \pi I_2 - cV \end{aligned}$$




[1] Nowak et al. *Proc Natl Acad Sci* 1996

[2] Ho et al. *Nature* 1995

[3] Stafford et al. *J Ther Biol* 2000

Viral dynamics

- Viral dynamics is the mathematical study of virus infection and dynamics within individuals
- Viral dynamic models aim to explain pathogenesis and biological processes in a viral infection
- Target cell model^[1,2,3]:



$$\frac{dT}{dt} = -\beta TV$$

$$\frac{dI_1}{dt} = \beta TV - kI_1$$

$$\frac{dI_2}{dt} = kI_1 - \delta I_2$$

$$\frac{dV}{dt} = \pi I_2 - cV$$

Table 1. HBV versus HIV dynamics

	HBV ^[1]	HIV ^[2,3]
Plasma virus		
Half-life	24 hr	6 hr
Daily turn-over	50%	90%
Total production (periphery)	10 ¹¹	10 ⁹
Load	2 × 10 ¹¹	10 ⁹
Infected cell		
Half-life	10–100 days	2 days
Daily-turnover	1–7%	30%

[1] Nowak et al. *Proc Natl Acad Sci* 1996

[2] Ho et al. *Nature* 1995

[3] Stafford et al. *J Ther Biol* 2000

Challenges in viral dynamics

- Some parameters of complex viral dynamics models can hardly be estimated
 - Parameters related to unobserved compartments
 - Poorly identifiable parameters are often fixed to arbitrary values^[1,2]
 - Sensitivity analyses are carried out^[2,3]

[1] Guedj et al *Bull Math Biol* 2007


[2] Handel et al *J R Soc Interface* 2010

[3] Best et al *Proc Natl Acad Sci* 2017


Challenges in viral dynamics

- Some parameters of complex viral dynamics models can hardly be estimated
 - Parameters related to unobserved compartments
 - Poorly identifiable parameters are often fixed to arbitrary values^[1,2]
 - Sensitivity analyses are carried out^[2,3]
- Various complex models can also be used to compare different biological assumptions^[4,5,6]
 - Ex: Influenza A


A Target cell depletion model



B Innate immunity model



C Adaptive immunity model



[1] Guedj et al *Bull Math Biol* 2007

[2] Handel et al *J R Soc Interface* 2010

[3] Best et al *Proc Natl Acad Sci* 2017

[4] Moore et al *Bull Math Biol* 2018

[5] Li and Handel *J Theor Biol.* 2014

[6] Baccam et al *J Virol.* 2006

Model selection

- Model selection (MS):
 - Most commonly used approach
 - Model that « best » describes the data, based on an information criteria (e.g. AIC)
 - Selected model is carried forward in prediction step
 - Ignores model uncertainty^[1]
 - Impairs predictive performances^[2,3]

[1] Buckland et al. *Biometrics* 1997

[2] Ganusov *Front Microbiol* 2016

[3] Evans et al. *Trends Ecol Evol* 2013

Model averaging

- Model averaging (MA):
 - Allows measuring model uncertainty by weighting a set of M candidate models in function of an information criteria^[1] (e.g. AIC)

$$w_m = \frac{e^{\frac{-AIC_m}{2}}}{\sum_{m=1}^M e^{\frac{-AIC_m}{2}}}$$

- Applications to NL^[2,3] and NLME models^[4,5,6]
 - Concentration-effect relationship
 - Dose finding studies

[1] Buckland et al. *Biometrics* 1997

[2] Ganusov *Front Microbiol* 2016

[3] Evans et al. *Trends Ecol Evol* 2013

[4] Dosne et al. *Stat Med* 2016

[5] Buatois et al. *AAPS* 2018


[6] Aoki et al. *JPSPD* 2017

Objectives

- To develop model averaging as an alternative to model selection in viral dynamic models
- To compare parameter estimates and predictive performances of model averaging and model selection in the context of:
 - 1) Poorly identifiable parameters
 - 2) Multiple biological models

Setting 1: viral dynamic models in presence of poorly identifiable parameters

- Target cell limited model^[1,2,3]:




- Expected RSE% using PFIM^[4]:
 - N = 30
 - Design = 3, 6, 9, 12, 15 and 18 days

Parameter (units)	Estimation of R ₀ , δ, V ₀ , k and π	
	Estimate	Expected RSE%
R ₀	12	516%
δ (d ⁻¹)	1	10.8%
c (d ⁻¹)	20 (fixed)	-
T ₀ (cells.mL ⁻¹)	10 ⁸ (fixed)	-
V ₀ (copies.mL ⁻¹)	10 ⁻⁴	743%
k (d ⁻¹)	4	971%
π (copie.cell ⁻¹ .d ⁻¹)	6000	604%
ω R ₀	0.3	28.6%
ω δ	0.3	41%
ω π	0.3	460%
σ	0.7	7%

[1] Smith et al *PLoS Pathog* 2013
[2] Handel et al *J R Soc Interface* 2010
[3] Best et al *Proc Natl Acad Sci* 2017
[4] Dumont et al. *Comput Methods Programs Biomed* 2018

Setting 1: viral dynamic models in presence of poorly identifiable parameters

- Target cell limited model^[1,2,3]:



- Expected RSE% using PFIM^[4]:


- N = 30
- Design = 3, 6, 9, 12, 15 and 18 days

	Estimation of R_0 , δ , V_0 , k and π		Estimation restricted to R_0 , δ and k	
Parameter (units)	Estimate	Expected RSE%	Estimate	Expected RSE%
R_0	12	516%	12	7.0%
δ (d ⁻¹)	1	10.8%	1	6.3%
c (d ⁻¹)	20 (fixed)	-	20 (fixed)	-
T_0 (cells.mL ⁻¹)	10 ⁸ (fixed)	-	10 ⁸ (fixed)	-
V_0 (copies.mL ⁻¹)	10 ⁻⁴	743%	10 ⁻⁴ (fixed)	-
k (d ⁻¹)	4	971%	4 (fixed)	-
π (copie.cell ⁻¹ .d ⁻¹)	6000	604%	6000	24.1%
ωR_0	0.3	28.6%	0.3	28.6%
$\omega \delta$	0.3	41%	0.3	41%
$\omega \pi$	0.3	460%	0.3	460%
σ	0.7	7%	0.7	7%

[1] Smith et al *PLoS Pathog* 2013
[2] Handel et al *J R Soc Interface* 2010
[3] Best et al *Proc Natl Acad Sci* 2017
[4] Dumont et al. *Comput Methods Programs Biomed* 2018

Setting 1: viral dynamic models in presence of poorly identifiable parameters

- We defined M=9 candidate models resulting from the combination of 3 values for V_0 and $k^{[1]}$:
 - $V_0 = 10^{-5}; 10^{-4}$ or 10^{-3} copies.mL $^{-1}$
 - $k = 1; 4$ or 20 d $^{-1}$




Parameters Ψ_m^*	μ	Ω
R_0	12	0.3
δ (d $^{-1}$)	1	0.3
π (copies.cell $^{-1}$.mL $^{-1}$)	6000	0.3
c (d $^{-1}$) fixed	20	-
V_0 (copies.mL $^{-1}$) fixed	$10^{-5}; 10^{-4}$ or 10^{-3}	-
k (d $^{-1}$) fixed	1, 4 or 20	-
σ	0.7	-

Setting 2: viral dynamic models including the immune response

- 4 models additional models to account for immunity roles during infection can be derived from a target cell model^[1,2,3,4]

Target cell limited
model (TCL)



$$\begin{aligned}\frac{dT}{dt} &= -\beta TV \\ \frac{dI_1}{dt} &= \beta TV - kI_1 \\ \frac{dI_2}{dt} &= kI_1 - \delta I_2 \\ \frac{dV}{dt} &= \pi I_2 - cV\end{aligned}$$

[1] Madelain et al. *Nat Commun* 2018


[2] Baccam et al. *J Virol* 2006

[3] Pawelek et al. *PLoS Comp Biol* 2012

[4] Li and Handel *J Theor Biol.* 2014

Setting 2: viral dynamic models including the immune response

- 4 models additional models to account for immunity roles during infection can be derived from a target cell model^[1,2,3,4]



$$\frac{dT}{dt} = -\beta TV - \frac{\phi TF}{F + \theta}$$

$$\frac{dI_1}{dt} = \beta TV - kI_1$$

$$\frac{dI_2}{dt} = kI_1 - \delta I_2$$

$$\frac{dV}{dt} = \pi I_2 - cV$$

$$\frac{dF}{dt} = qI_2 - d_F F$$

[1] Madelain et al. *Nat Commun* 2018


[2] Baccam et al. *J Virol* 2006

[3] Pawelek et al. *PLoS Comp Biol* 2012

[4] Li and Handel *J Theor Biol* 2014

Setting 2: viral dynamic models including the immune response

- 4 models additional models to account for immunity roles during infection can be derived from a target cell model^[1,2,3,4]



$$\frac{dT}{dt} = -\beta TV$$

$$\frac{dI_1}{dt} = \beta TV - kI_1$$

$$\frac{dI_2}{dt} = kI_1 - \delta I_2$$

$$\frac{dV}{dt} = \pi \left(1 - \frac{\phi F}{F + \theta} \right) I_2 - cV$$

$$\frac{dF}{dt} = qI_2 - d_F F$$

[1] Madelain et al. *Nat Commun* 2018



[2] Baccam et al. *J Virol* 2006

[3] Pawelek et al. *PLoS Comp Biol* 2012

[4] Li and Handel *J Theor Biol* 2014

Setting 2: viral dynamic models including the immune response

- 4 models additional models to account for immunity roles during infection can be derived from a target cell model^[1,2,3,4]



$$\frac{dT}{dt} = -\beta TV$$

$$\frac{dI_1}{dt} = \beta TV - kI_1$$

$$\frac{dI_2}{dt} = kI_1 - \delta I_2 - \frac{\phi I_2 F}{F + \theta}$$

$$\frac{dV}{dt} = \pi I_2 - cV$$

$$\frac{dF}{dt} = qI_2 - d_F F$$

[1] Madelain et al. *Nat Commun* 2018



[2] Baccam et al. *J Virol* 2006

[3] Pawelek et al *PLoS Comp Biol* 2012

[4] Li and Handel *J Theor Biol.* 2014

Setting 2: viral dynamic models including the immune response

- 4 models additional models to account for immunity roles during infection can be derived from a target cell model^[1,2,3,4]



$$\frac{dT}{dt} = -\beta TV$$

$$\frac{dI_1}{dt} = \beta TV - kI_1$$

$$\frac{dI_2}{dt} = kI_1 - \delta I_2$$

$$\frac{dV}{dt} = \pi I_2 - cV - \frac{\phi FV}{F + \theta}$$

$$\frac{dF}{dt} = qI_2 - d_F F$$

[1] Madelain et al. *Nat Commun* 2018

[2] Baccam et al. *J Virol* 2006


[3] Pawelek et al *PLoS Comp Biol* 2012

[4] Li and Handel *J Theor Biol.* 2014

Setting 2: viral dynamic models including the immune response

- We defined M=5 candidate models^[1,2,3,4]
 - Parameters chosen to provide a 20% reduction of the log AUC_{0→20} in presence of immune response

Parameters Ψ_m^*	TCL	R	PI	C	V	ω
π (copies.cell ⁻¹ .mL ⁻¹)	250	6000	6000	6000	6000	0.3
θ	0	2200	32.5.10 ⁴	3	0.001	-
ϕ	0	1	0.99	0.9	36.5	0.3
R_0	12					0.3
δ (d ⁻¹)	1					0.3
c (d ⁻¹) fixed	20					-
V_0 (copies.mL ⁻¹) fixed	10 ⁻⁴					-
k (d ⁻¹) fixed	4					-



[1] Madelain et al. *Nat Commun* 2018


[2] Baccam et al. *J Virol* 2006

[3] Pawelek et al. *PLoS Comp Biol* 2012

[4] Li and Handel *J Theor Biol* 2014

Simulations & estimation

Simulation scenario:




Estimation:

- Estimation of $\hat{\Psi}_m^s$ by maximizing the likelihood function
 - SAEM algorithm using importance sampling
- Asymptotic approximation of $p(\hat{\Psi}_m^s)$ supposed Gaussian with standard errors given by FIM^{-1}
- MONOLIX version 2018 release 2

Simulations & estimation

Simulation scenario:




Estimation:

- Estimation of $\hat{\Psi}_m^s$ by maximizing the likelihood function
 - SAEM algorithm using importance sampling
- Asymptotic approximation of $p(\hat{\Psi}_m^s)$ supposed Gaussian with standard errors given by FIM^{-1}
- MONOLIX version 2018 release 2

Simulations & estimation

Simulation scenario:



Estimation:


- Estimation of $\hat{\Psi}_m^s$ by maximizing the likelihood function
 - SAEM algorithm using importance sampling
- Asymptotic approximation of $p(\hat{\Psi}_m^s)$ supposed Gaussian with standard errors given by FIM^{-1}
- MONOLIX version 2018 release 2

$$p(\hat{\Psi}_{MA}^s) = \sum_{m=1}^M w_m^s p(\hat{\Psi}_m^s)$$

Performances of MS and MA for parameter estimation

For each setting, scenario and approach:

- Percentage of selected models
- Distribution of weights
- Coverage rates (CR) of parameters R_0 and δ




$$CR = \frac{1}{S} \sum_{s=1}^S \mathbb{1}_{\psi_m^* \in CI_{95\%}(\hat{\psi}_m^s)}$$

Setting 1: viral dynamic models in presence of poorly identifiable parameters

Percentage of selected models





Simulation scenario



Setting 1: viral dynamic models in presence of poorly identifiable parameters

Percentage of selected models

Simulation scenario





Selected model \neq simulation model

Setting 1: viral dynamic models in presence of poorly identifiable parameters

Percentage of selected models & distribution of weights


Simulation scenario



Selected model \neq simulation model


Setting 1: viral dynamic models in presence of poorly identifiable parameters

Coverage rates




Setting 1: viral dynamic models in presence of poorly identifiable parameters

Coverage rates




Setting 1: viral dynamic models in presence of poorly identifiable parameters

Coverage rates



Setting 2: viral dynamic models including the immune response


Percentage of selected models



Setting 2: viral dynamic models including the immune response


Percentage of selected models & distribution of weights

Simulation scenario




Setting 2: viral dynamic models including the immune response

Coverage rates




Setting 2: viral dynamic models including the immune response

Coverage rates





Setting 2: viral dynamic models including the immune response

Coverage rates





Predictive performances of MS and MA







- Capability of MS and MA to anticipate the effect of a treatment

Predictive performances of MS and MA



- Capability of MS and MA to anticipate the effect of a treatment
- Treatment initiated at day 6 and up to day 20

Predictive performances of MS and MA




- Capability of MS and MA to anticipate the effect of a treatment
- Treatment initiated at day 6 and up to day 20

$$P_m^S = \Pr(V_m^S(t = 20) < LLOQ)$$


Predictive performances of MS and MA

- Prediction of the percentage of patients with undetectable viral load (i.e. below 10 copies.mL⁻¹) at EoT
- 3 levels of efficacy: 90,95 or 99% initiated at day 6 and up to day 20



Predictive performances of MS and MA

- Prediction of the percentage of patients with undetectable viral load (i.e. below 10 copies.mL⁻¹) at EoT
- 3 levels of efficacy: 90,95 or 99% initiated at day 6 and up to day 20




MS


$$P_{MS}^s = Pr(V_{MS}^s(t = 20) < LLOQ)$$

Predictive performances of MS and MA


- Prediction of the percentage of patients with undetectable viral load (i.e. below 10 copies.mL⁻¹) at EoT
- 3 levels of efficacy: 90,95 or 99% initiated at day 6 and up to day 20



Predicted percentage of undetectable viral loads



Predicted percentage of undetectable viral loads



Conclusion

- MS in viral dynamics can lead to poor coverage rates for parameter estimates
- MA can improve coverages by taking into account both parameter and model uncertainty
- MS has provided good predictions in our scenarios
 - ➔ MA is easy to implement and should be used to refine parameter estimates and predictions

Perspectives

- Explore settings where the true model is not part of the candidate models
- Find an alternative to asymptotic approximation for parameter uncertainties
 - Implement other methods to compute the FIM such as HMC^[1] or SIR^[2]

[1] Ueckert et al. 2015

[2] Dosne et al. *J Pharmacokinet Pharmacodyn* 2016

Announcement



4th Workshop on Viral Dynamics 21-23 October 2019 - Paris, France



Organizers: - Jérémie Guedj, INSERM, jeremie.guedj@inserm.fr

- Mélanie Prague, INRIA Bordeaux, melanie.prague@inria.fr

See info: <https://viraldynamics.sciencesconf.org/>

Acknowledgements

- To the co-authors

Annabelle LEMENUUEL-DIOT

France MENTRE

Jérémie GUEDJ

- To my Inserm colleagues



- To Roche

